In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of aplaviroc

Journal of Clinical Pharmacology

Volumn 48, Issue 10, 2008, Pages 1179-1188

  Demarest, James F ^a   Sparks, Sara S ^a   Schell, Kathleen ^b   Shibayama, Shiro ^c   McDanal, Charlene B ^a   Fang, Lei ^a   Adkison, Kimberly K ^a   Shachoy Clark, Anne ^a   Piscitelli, Stephen C ^a  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c ONO PHARMACEUTICAL CO   (Japan)

Author keywords

CCR5; HIV; Receptor occupancy

Indexed keywords

APLAVIROC; CHEMOKINE RECEPTOR CCR5; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 45531; UNCLASSIFIED DRUG;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MALE; RECEPTOR OCCUPANCY;

ADULT; ANTIBODIES, MONOCLONAL; BENZOATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FLOW CYTOMETRY; HALF-LIFE; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN BINDING; RECEPTORS, CCR5; RNA, VIRAL; SPIRO COMPOUNDS; TIME FACTORS; YOUNG ADULT;

EID: 51849148494     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008322178     Document Type: Article

References (24)

1. Grant RM, Hecht FM, Warmerdam M., et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA. 2002 ; 288 (2). 181-188.
2. Richman DD, Morton SC, Wrin T., et al. The prevalence of antiretroviral drug resistance in the United States. AIDS. 2004 ; 18 (10). 1393-1401.
3. Berger EA, Murphy PM, Farber JM Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol. 1999 ; 17: 657-700.
4. Lalezari JP, Henry K., O'Hearn M., et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003 ; 348 (22). 2175-2185.
5. Lazzarin A., Clotet B., Cooper D., et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003 ; 348 (22). 2186-2195.
6. Fujii N., Nakashima H., Tamamura H. The therapeutic potential of CXCR4 antagonists in the treatment of HIV. Expert Opin Investig Drugs. 2003 ; 12 (2). 185-195.
7. Kazmierski W., Bifulco N., Yang H., et al. Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors. Bioorg Med Chem. 2003 ; 11 (13). 2663-2676.
8. Drews J. Drug discovery: a historical perspective. Science. 2000 ; 287 (5460). 1960-1964.
9. Maeda K., Nakata H., Koh Y., et al. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J Virol. 2004 ; 78 (16). 8654-8662.
10. Lalezari J., Thompson M., Kumar P., et al. Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults. AIDS. 2005 ; 19 (14). 1443-1448.
11. Adkison KK, Shachoy-Clark A., Fang L., et al. Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects. Antimicrob Agents Chemother. 2005 ; 49 (7). 2802-2806.
12. Watson C., Jenkinson S., Kazmierski W., Kenakin T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol. 2005 ; 67 (4). 1268-1282.
13. Schwartz O., Henin Y., Marechal V., et al. A rapid and simple colorimetric test for the study of anti-HIV agents. AIDS Res Hum Retroviruses. 1988 ; 4 (6). 441-448.
14. Adkison K., Fang L., Shachoy-Clark A., et al. The pharmacokinetic (PK) interaction between the entry inhibitor aplaviroc (APL, 873140) and efavirenz in healthy adults. Poster presented at the 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ; December 18, 2005 ; Washington, DC, Poster #A-1197.
15. Lee B., Sharron M., Montaner LJ, Weissman D., Doms RW Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci U S A. 1999 ; 96 (9). 5215-5220.
16. Weinstock HS, Zaidi I., Heneine W., et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis. 2004 ; 189 (12). 2174-2180.
17. Pozniak AL, Fatkenhauer G., Johnson M., et al. Effect of short-term monotherapy with UK-427 857 on viral load in HIV-infected patients. Paper presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ; September 14-17, 2003 ; Chicago, Ill. Abstract #H-443.
18. Schurmann D., Rouzier R., Nougarede R., et al. SCH D.: antiviral activity of a CCR5 receptor antagonist. Paper presented at: 11th Conference on Retroviruses and Opportunistic Infections ; February 8-11, 2004 ; San Francisco, CA. Abstract #140LB.
19. Veazey RS, Klasse PJ, Ketas TJ, et al. Use of a small-molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J Exp Med. 2003 ; 198 (10). 1551-1562.
20. Cannon CP, McCabe CH, Borzak S. et al. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in myocardial infarction. Circulation. 1998 ; 97 (4). 340-349.
21. Hezard N., Metz D., Nazeyrollas P., et al. Free and total platelet glycoprotein IIb/IIIa measurement in whole blood by quantitative flow cytometry during and after infusion of c7E3 Fab in patients undergoing PTCA. Thromb Haemost. 1999 ; 81 (6). 869-873.
22. Kereiakes DJ, Kleiman NS, Ferguson JJ, et al. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial. Circulation. 1998 ; 98 (13). 1268-1278.
23. Quinn M., Deering A., Stewart M., Cox D., Foley B., Fitzgerald D. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists. Circulation. 1999 ; 99 (17). 2231-2238.
24. Quinn MJ, Murphy RT, Dooley M., Foley JB, Fitzgerald DJ Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion. J Pharmacol Exp Ther. 2001 ; 297 (2). 496-500.